

Supporting Information

1-Methyl-3-{4-[(4-(2-oxo-2,3-dihydro-1*H*-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-2-phenylindole


Jean Guillon ^{1,*}, Solène Savrimoutou ¹, Sandra Rubio ¹ and Vanessa Desplat ²


¹ Univ. Bordeaux, UFR des Sciences Pharmaceutiques, INSERM U1212 / UMR CNRS 5320, Laboratoire ARNA, 146 rue Léo Saignat, F-33076 Bordeaux cedex, France; jean.guillon@u-bordeaux.fr (J.G.) ; solene.savrimoutou@u-bordeaux.fr (S.S.) ; sandra.rubio@u-bordeaux.fr (S.R.)


² Univ. Bordeaux, INSERM U1035, Cellules souches hématopoïétiques normales et leucémiques, UFR des Sciences Pharmaceutiques, 33076 Bordeaux cedex, France; vanessa.desplat@u-bordeaux.fr (V.D.)


* Correspondence: jean.guillon@u-bordeaux.fr; Tel.: +33-557571652


Contents	Page
¹ H-NMR spectrum of compound 1	S2
¹³ C-NMR spectrum of compound 1	S3
JMOD-NMR spectrum of compound 1	S4
HSQC-NMR spectrum of compound 1	S5
FT-IR spectrum of compound 1	S6
HRMS data for compound 1	S7-S8














180918-Exac-6173-JG-JG687 #1-27 RT: 0.04-0.42 AV: 27 NL: 1.07E8

T: FTMS + p ESI Full ms [150.00-3000.00]

